Protagonist Therapeutics (PTGX) Tops Q2 EPS by 16c

Protagonist Therapeutics (NASDAQ: PTGX) reported Q2 EPS of $2.29, $0.16 better than the analyst estimate of $2.13. Revenue for the quarter came in at $213.47 million versus the consensus estimate of $190.12 million.

For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Deutsche Bank Upgrades Huizhou Desay Sv Automotive Co (002920:CH) to Hold
• JPMorgan Downgrades HomeCo Daily Needs REIT (HDN:AU) to Neutral